c-Met Overexpression in Cervical Cancer, a Prognostic Factor and a Potential Molecular Therapeutic Target-Reference-Cited by-同舟云学术

c-Met Overexpression in Cervical Cancer, a Prognostic Factor and a Potential Molecular Therapeutic Target

Published:2017-12 Issue:6 Volume:40 Page:590-597
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Refaat Tamer,Donnelly Eric D.,Sachdev Sean,Parimi Vamsi,El Achy Samar,Dalal Prarthana,Farouk Mohamed,Berg Natasha,Helenowski Irene,Gross Jeffrey P.,Lurain John,Strauss Jonathan B.,Woloschak Gayle,Wei Jian-Jun,Small William

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference37 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014

3. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01;Eifel;J Clin Oncol,2004

4. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer;Morris;N Engl J Med,1999

5. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix;Pearcey;J Clin Oncol,2002

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic reprogramming directed by super-enhancers in tumors: An emerging landscape;Molecular Therapy;2024-03

2. Numb suppression promoted the pathogenesis of SiHa cells by stimulating Notch and Hedgehog signaling pathways;Gynecology and Pelvic Medicine;2023-12

3. Signal Pathways and microRNAs in Osteosarcoma Growth and the Dual Role of Mesenchymal Stem Cells in Oncogenesis;International Journal of Molecular Sciences;2023-05-19

4. Genomic alterations associated with mutational signatures, DNA damage repair and chromatin remodeling pathways in cervical carcinoma;npj Genomic Medicine;2021-10-07

5. CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure;BMC Cancer;2021-09-25